Home
Login
Help
Search this site:
Registered Trials
By recruitment status
By sponsor
By registration date
Advanced search for trials
Registration process
To register a trial
Sponsor registration form
RPCEC trial registration Data Set
To update a registered trial
To disclosure the results of registered trial
Home
|
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX
View current
Revisions
List all revisions
View
Compare to current
21 May 2021 - 4:50pm
by Gladys
19 July 2023 - 3:28pm
by Gladys
Changes to
Record Verification Date
-
2021/
05
/
21
+
2021/
06
/
15
Changes to
Next update date
-
2022/
05
/
21
+
2022/
06
/
15
Revision of 19 July 2023 - 3:28pm:
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX
General information
Section to complete general information about the trial: scientific and public title, protocol identifiers, sponsors and Source(s) of Monetary or Material Support.
Acronym of Public Title:
PREVAX
Scientific title:
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX
Acronym of Scientific Title:
PREVAX
Secondary indentifying numbers:
Not applicable
Issuing authority of the secondary identifying numbers:
Not applicable
Primary sponsor:
Center of Molecular Immunology (CIM)
Secondary sponsor:
Hermanos Ameijeiras Clinical Surgical Hospital (HHA)
Source(s) of monetary or material support:
Cuban Ministry of Public Health (MINSAP), Center of Molecular Immunology (CIM)
Authorization for beginning
Section to complete information about the regulatory approval of clinical trial: regulatory agency name, approval date and reference number in the agency.
Regulatory instance to authorize the initiation of the study:
Trials notification
Regulatory instance:
Center for State Control of Drugs, Medical Devices and Equipment (CECMED)
Reference number:
In process
Principal investigator
Section to complete information about Email address, telephone number and postal address of the Principal Investigator.
First name:
Pedro
Midle name:
Pablo
Last name:
Pino Alfonso
Medical Specialty :
Second Degree Specialist in Pulmonology
Affiliation:
Hermanos Ameijeiras Clinical Surgical Hospital (HHA)
Postal address:
San Lazaro 701 corner Belascoain. Centro Habana.
City:
Havana
Country:
Cuba
Zip Code:
10300
Telephone:
+53-78761436
Email address:
broncoscopia@hha.sld.cu
Clinical sites to participate
Section to complete the data related to the clinical sites involved in the trial: site and responsible investigator for every site.
Countries of recruitment:
Cuba
Clinical sites:
Not applicable
Recruitment status
Section to complete information about the recruitment status and the date of first enrolment subject
Recruitment status:
Pending
Date of first enrollment:
01/06/2021
Health condition and Intervention
Section to complete information about the primary medical condition(s) or problem(s) studied and, a characteristics of the intervention(s).
Health condition(s) or Problem(s) studied:
Lung cancer
Health condition(s) code:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Intervention(s):
CIMAvax®-EGF (Experimental group). CIMAvax®-EGF, 2.4 mg per dose. The first 4 doses will be administered every 14 days and the remaining 4 doses, every 28 days until reaching 8 doses. The duration of the treatment will be 6 months. The product will be administered intramuscularly divided into 4 subdoses, equivalent to 0.6 mg of EGF at each site of inoculation (both deltoid regions and both glutes). Prior to receiving the first dose of the vaccine (72 hours), patients will receive a single dose of cyclophosphamide (CMF) 200 mg / m2 intravenously.
Intervention code:
Immunotherapy, Active
Epidermal Growth Factor
Cyclophosphamide
Injections, Intramuscular
Administration, Intravenous
Intervention keyword:
CIMAvax-EGF
Outcomes and Timepoint
Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
1. EGF concentration (the EGF concentration in the blood of the patients expressed in pg / mL will be determined). Measurement time: At baseline, 14 days (+3) from the end of the induction phase (4th dose of the vaccine) and 14 days (+3) from the evaluation at the end of the study treatment (8th dose of the vaccine) . 2. Anti-EGF antibody titers (measurement of anti-EGF antibody titers will be performed in response to short-term vaccination and will determine if it is ≥ 1: 4000). Measurement time: At baseline, 14 days (+3) after the end of the induction phase (4th dose of the vaccine) and 14 days (+3) after the evaluation at the end of the study treatment (8th dose of the vaccine). 3. Serum IL-6 concentration. (pg / ml). Measurement time: At baseline, weeks 8 and 24. 4. Total bilirubin. (mg / dL). Measurement time: At baseline, weeks 8 and 24. 5. Neutrophil / lymphocyte ratio (neutrophil / lymphocyte ratio). Measurement time: At baseline, weeks 8 and 24. 6. Platelet / lymphocyte ratio (platelet / lymphocyte ratio). Measurement time: At baseline, weeks 8 and 24. 7. Absolute count and frequency of CD4 + T cells (total and%). Measurement time: At baseline, weeks 8 and 24. 7. 8. Absolute count and frequency of CD8 + T cells (total and%). Measurement time: At baseline, weeks 8 and 24. 8. 9. CD4 / CD8 Index (CD4 / CD8 Ratio). Measurement time At baseline, weeks 8 and 24.
Key secondary outcomes:
1. (Occurrence of an AE (Yes, No), Type of AE (according to the CTC version 5.0 nomenclature), Duration of the AE (Differences between the start and end dates of the AE), Intensity of the AE (Light, Moderate, Severe, Severe threatening or incapacitating, Severe causing death, according to CTC version 5.0), Causation of AE (Definitive, Very likely, Probable, Possible, Unrelated, Unknown), Severity of AE (Yes, No. In case of seriousness, it will be classified according to the categories of: causes the death of the patient, threatens life, requires hospitalization or prolongs an existing hospitalization, produces a disability, significant or persistent disability, produces a birth defect or a congenital anomaly), Attitude versus the treatment under study (No changes, Dose modification, Temporary interruption of treatment, Definitive interruption of treatment, according to the attitude decided by the clinical investigator), AE Result (Recovered, Improved, Persists, Sec uelas)). Measurement time: Weeks 0, 2, 4, 6, 8, 10, 14, 18, 22, 24 and 30. 2. Clinical response (For patients included in Cohort A, it will be evaluated through the respiratory function test and the COPD status will be collected at the end of treatment according to the GOLD criteria. For patients included in Cohort B, it will be evaluated through imaging and will collect the control of the disease in local relapse or relapse at a distance). Measurement time: At baseline, and at week 24 from the beginning of CIMAvax-EGF treatment.
Selection criterias
Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Gender:
Male/Female
Minimum age:
18 years
Maximum age:
79 years
Inclusion criteria:
1. Patients who meet the diagnostic criteria according to the cohort to which they belong. 2. Patients aged ≥ 18 years for lung cancer survivors and between 50 and 79 years for patients at high risk of lung cancer. 3. Patients who do not have imaging evidence of lung cancer, evaluated by CT according to RECIST criteria. 4. Patients of childbearing potential who consent to the use of adequate contraceptive methods (eg, hormonal or barrier methods of contraception, abstinence) before being included in the study. If a woman becomes pregnant or suspects that she is pregnant while she or her partner is participating in this study, she should inform her doctor immediately. 5. Patients who give their informed consent for participation in writing. In addition to the above criteria, patients must meet the following criteria specific to the cohort in which they will be included: Patients at high risk of lung cancer (Cohort A). 1. Document the presence of any of these risk factors • Moderate or severe COPD. • Family history of lung cancer. • Low body mass index. • Recent pneumonia. 2. Have quit smoking in the last 10 years or be a current smoker. 3. Have a history of smoking at least 50 packs / year. 4. Have a pulmonary function test in the last 3 months before inclusion. Early Stage Lung Cancer Survivors (Cohort B). 1. Completion of adjuvant therapy for lung cancer after surgery 3 months prior to enrollment, with no evidence of early disease progression. 2. NSCLC confirmed stage IB to IIIA at initial diagnosis (TNM 8th edition).
Exclusion criteria:
1. Patients clinically unfit to undergo the bronchoscopy procedure. 2. Patients with uncontrolled intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. 3. Stage IIIA non-surgical patients. 4. Patients with mild or very severe COPD. 5. Patients with psychiatric illness and / or social situations that would limit compliance with the study requirements. 6. Pregnant or lactating patients. 7. Patients with other malignancy in the previous 5 years, except skin cancer (non-melanoma). 8. Patients who have received another investigational product within 30 days prior to inclusion. 9. Patients who have received treatment for their disease with immunotherapy. 10. Patients with known immunosuppressive disease (eg, HIV, AIDS, or other immunosuppressive disease). The test is not mandatory. 11. Patients with known hypersensitivity to the components of the vaccine under study or any analogue. 12. Patients requiring steroid treatment equivalent to doses greater than 20 mg of prednisone per day. 13. Patients reluctant or unable to follow the requirements of the protocol
Type of population:
Adults
Type of participant:
Patients
Study design
Section to complete information about the characteristics of the study design.
Type study:
Interventional
Purpose:
Prevention
Allocation:
N/A: single arm study
Masking:
Open
Control group:
Uncontrolled
Study design:
Single group
Phase:
1
Target sample size:
60
Contact for public queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to general queries, including information about current recruitment status
First Name:
Orestes
Middle Name:
Santos
Last Name:
Morales
Specialty:
Second Degree Specialist in Pharmacology
Affiliation:
Center of Molecular Immunology (CIM)
Postal Address:
Street 216, corner 15, Reparto Atabey. Playa
City:
Havana
Country:
Cuba
Zip Code:
11600
Telephone:
+53-72143144
Email :
orestesm@cim.sld.cu
Contact for scientific queries
Section to complete information about Email address, telephone number and postal address of the contact who will respond to scientific queries.
First Name:
Pedro
Middle Name:
Pablo
Last Name:
Pino Alfonso
Specialty:
Second Degree Specialist in Pulmonology
Affiliation:
Hermanos Ameijeiras Clinical Surgical Hospital (HHA)
Postal Address:
San Lazaro 701 corner Belascoain. Centro Habana.
City:
Havana
Country:
Cuba
Zip Code:
10300
Telephone:
+53-78761436
Email :
broncoscopia@hha.sld.cu
Data Sharing
Section to complete the data related to the data sharing plan.
Data sharing plan:
No
Research Ethics Committees
Section to complete the data related to the review ethics committees.
Name of Research Ethics Committees:
Hermanos Ameijeiras Clinical Surgical Hospital (HHA)
Status of evaluation:
In review
Status of evaluation date of Ethic Committee:
07/04/2021
Postal address of Ethic Committee :
San Lazaro 701 corner Belascoain, Centro Habana, Havana, ZC 10300, Cuba
Telephone:
+53-78761000
Email:
direccion@hha.sld.cu
About study completion
Section to complete the data related to the study completion.
Study completion date:
31/01/2023
Date of available results:
29/09/2023
Date of first publication:
29/12/2023
Registration and Update
Section to complete information about the name of Primary Registry, date of registration and the unique ID number assigned by the registry (RPCEC).
Primary registry:
RPCEC
Unique ID number:
RPCEC00000370
Date of Registration in Primary Registry:
21/05/2021
Record Verification Date:
2021/06/15
Next update date:
2022/06/15
Link to the spanish version:
Click here
About the RPCEC
Structure and governance
Policy
Publications
Awards
Communications
News
Useful resources
Fundamentals of the registry
References of clinical trials
Cuban regulations
Other registries
International Clinical Trials Registry Platform